The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma.
 
Ciara Conduit
No Relationships to Disclose
 
Ganessan Kichenadasse
No Relationships to Disclose
 
Carole A. Harris
Consulting or Advisory Role - BMS (Inst); Merck; MSD (Inst); Pfizer
 
Howard Gurney
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; Pfizer; Roche
Speakers' Bureau - Merck Serono
Travel, Accommodations, Expenses - AstraZeneca
 
Tom Ferguson
Research Funding - AstraZeneca (Inst); Janssen (Inst); MSD (Inst)
Travel, Accommodations, Expenses - BMS; MSD; Roche
 
Francis Parnis
Stock and Other Ownership Interests - Telix Pharmaceuticals
Consulting or Advisory Role - Ipsen; Janssen Oncology; Merck Serono
 
Jeffrey C. Goh
Stock and Other Ownership Interests - ICON Cancer Care; Immutep
Honoraria - Ipsen; MSD Oncology
Consulting or Advisory Role - BMS; GlaxoSmithKline; Janssen Oncology; MSD
Speakers' Bureau - AstraZeneca/MedImmune; BMS; Ipsen; Janssen; MSD Oncology
Research Funding - BeiGene (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Michelle Frances Morris
No Relationships to Disclose
 
Craig Underhill
Consulting or Advisory Role - AstraZeneca; Bayer; Merck Serono
Speakers' Bureau - AstraZeneca; IQvia
Research Funding - Akeso Biopharma (Inst); Arcus Biosciences (Inst); AtriCure (Inst); BeyondSpring Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Deciphera (Inst); novotech (Inst)
 
David William Pook
Honoraria - Bayer
Consulting or Advisory Role - Astellas Pharma; Bristol Myers Squibb Foundation; Bristol-Myers Squibb; Bristol-Myers Squibb; Cipla; Merck; Merck Sharp & Dohme; Merck Sharp & Dohme (Inst); Merck/Pfizer; Pfizer; Pfizer (Inst)
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); SymVivo (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Astellas Pharma; Bristol-Myers Squibb; Pfizer
 
Ian D. Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Medivation (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
 
Felicia Roncolato
No Relationships to Disclose
 
Michelle L. Harrison
Stock and Other Ownership Interests - CSL Limited (I)
Consulting or Advisory Role - GlaxoSmithKline (Inst)
 
Stephen Begbie
Consulting or Advisory Role - Astellas Pharma; Janssen Oncology; Merck Serono; MSD Oncology
Research Funding - Astellas Medivation (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck Serono (Inst); MSD (Inst); Pfizer/EMD Serono (Inst); Roche (Inst)
 
Anthony M. Joshua
Stock and Other Ownership Interests - Pricilium Therapeutics
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Merck Serono (Inst); Neoleukin Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Emma Link
Patents, Royalties, Other Intellectual Property - Emma is an innovator: the discovery of her DPhil has been the subject of patent applications in the USA, UK, Europe, China, and Japan. The US rights to the patent were granted to Boston Heart Diagnostics which optimised the test on their technology platfo
 
Elizabeth J. Hovey
Consulting or Advisory Role - Ipsen; Janssen; Merck
 
Craig Gedye
Consulting or Advisory Role - Abbvie (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck Sharp & Dohme (Inst); Novotech; Pfizer (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst)